Review



anti cd47 reagent  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Bio X Cell anti cd47 reagent
    A , B Flow cytometry analysis and quantification of macrophages phagocytosis in GSC20 and GSC267 cells treated with IgG or blocking <t>antibody</t> <t>anti-CD47</t> and anti-IGFBP2. Right graph: Quantification of the percentage of macrophages phagocytosis. ( n = 3) C Schematic representation of the homologous models established to evaluate the response to anti-CD47 and anti-IGFBP2 therapy. D Bioluminescence imaging of xenograft models established with GSC267 cells treated with anti-CD47 and anti-IGFBP2 antibody on the indicated days after surgery. E In vivo tumor activities were assessed by bioluminescent in vivo imaging system on the indicated days after surgery. ( n = 5) F Kaplan-Meier survival curves for animals in different groups, n = 5 for each group. G A proposed model of hypoxia-exosomal IGFBP2-CD47 axis in the regulation of GBM immune evasion. Data are presented as the mean ± SD. Statistical significance was determined using one-way ANOVA and the log-rank test (* P < 0.05; ** P < 0.01; *** P < 0.001).
    Anti Cd47 Reagent, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 27 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd47+reagent/pmc12876975-59-6-9?v=Bio+X+Cell
    Average 93 stars, based on 27 article reviews
    anti cd47 reagent - by Bioz Stars, 2026-06
    93/100 stars

    Images

    1) Product Images from "Targeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma"

    Article Title: Targeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma

    Journal: Cell Death & Disease

    doi: 10.1038/s41419-026-08430-9

    A , B Flow cytometry analysis and quantification of macrophages phagocytosis in GSC20 and GSC267 cells treated with IgG or blocking antibody anti-CD47 and anti-IGFBP2. Right graph: Quantification of the percentage of macrophages phagocytosis. ( n = 3) C Schematic representation of the homologous models established to evaluate the response to anti-CD47 and anti-IGFBP2 therapy. D Bioluminescence imaging of xenograft models established with GSC267 cells treated with anti-CD47 and anti-IGFBP2 antibody on the indicated days after surgery. E In vivo tumor activities were assessed by bioluminescent in vivo imaging system on the indicated days after surgery. ( n = 5) F Kaplan-Meier survival curves for animals in different groups, n = 5 for each group. G A proposed model of hypoxia-exosomal IGFBP2-CD47 axis in the regulation of GBM immune evasion. Data are presented as the mean ± SD. Statistical significance was determined using one-way ANOVA and the log-rank test (* P < 0.05; ** P < 0.01; *** P < 0.001).
    Figure Legend Snippet: A , B Flow cytometry analysis and quantification of macrophages phagocytosis in GSC20 and GSC267 cells treated with IgG or blocking antibody anti-CD47 and anti-IGFBP2. Right graph: Quantification of the percentage of macrophages phagocytosis. ( n = 3) C Schematic representation of the homologous models established to evaluate the response to anti-CD47 and anti-IGFBP2 therapy. D Bioluminescence imaging of xenograft models established with GSC267 cells treated with anti-CD47 and anti-IGFBP2 antibody on the indicated days after surgery. E In vivo tumor activities were assessed by bioluminescent in vivo imaging system on the indicated days after surgery. ( n = 5) F Kaplan-Meier survival curves for animals in different groups, n = 5 for each group. G A proposed model of hypoxia-exosomal IGFBP2-CD47 axis in the regulation of GBM immune evasion. Data are presented as the mean ± SD. Statistical significance was determined using one-way ANOVA and the log-rank test (* P < 0.05; ** P < 0.01; *** P < 0.001).

    Techniques Used: Flow Cytometry, Blocking Assay, Imaging, In Vivo, In Vivo Imaging



    Similar Products

    anti cd47 reagent  (Bio X Cell)
    93
    Bio X Cell anti cd47 reagent
    A , B Flow cytometry analysis and quantification of macrophages phagocytosis in GSC20 and GSC267 cells treated with IgG or blocking <t>antibody</t> <t>anti-CD47</t> and anti-IGFBP2. Right graph: Quantification of the percentage of macrophages phagocytosis. ( n = 3) C Schematic representation of the homologous models established to evaluate the response to anti-CD47 and anti-IGFBP2 therapy. D Bioluminescence imaging of xenograft models established with GSC267 cells treated with anti-CD47 and anti-IGFBP2 antibody on the indicated days after surgery. E In vivo tumor activities were assessed by bioluminescent in vivo imaging system on the indicated days after surgery. ( n = 5) F Kaplan-Meier survival curves for animals in different groups, n = 5 for each group. G A proposed model of hypoxia-exosomal IGFBP2-CD47 axis in the regulation of GBM immune evasion. Data are presented as the mean ± SD. Statistical significance was determined using one-way ANOVA and the log-rank test (* P < 0.05; ** P < 0.01; *** P < 0.001).
    Anti Cd47 Reagent, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cd47+reagent/pmc12876975-59-6-9?v=Bio+X+Cell
    Average 93 stars, based on 1 article reviews
    anti cd47 reagent - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    A , B Flow cytometry analysis and quantification of macrophages phagocytosis in GSC20 and GSC267 cells treated with IgG or blocking antibody anti-CD47 and anti-IGFBP2. Right graph: Quantification of the percentage of macrophages phagocytosis. ( n = 3) C Schematic representation of the homologous models established to evaluate the response to anti-CD47 and anti-IGFBP2 therapy. D Bioluminescence imaging of xenograft models established with GSC267 cells treated with anti-CD47 and anti-IGFBP2 antibody on the indicated days after surgery. E In vivo tumor activities were assessed by bioluminescent in vivo imaging system on the indicated days after surgery. ( n = 5) F Kaplan-Meier survival curves for animals in different groups, n = 5 for each group. G A proposed model of hypoxia-exosomal IGFBP2-CD47 axis in the regulation of GBM immune evasion. Data are presented as the mean ± SD. Statistical significance was determined using one-way ANOVA and the log-rank test (* P < 0.05; ** P < 0.01; *** P < 0.001).

    Journal: Cell Death & Disease

    Article Title: Targeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma

    doi: 10.1038/s41419-026-08430-9

    Figure Lengend Snippet: A , B Flow cytometry analysis and quantification of macrophages phagocytosis in GSC20 and GSC267 cells treated with IgG or blocking antibody anti-CD47 and anti-IGFBP2. Right graph: Quantification of the percentage of macrophages phagocytosis. ( n = 3) C Schematic representation of the homologous models established to evaluate the response to anti-CD47 and anti-IGFBP2 therapy. D Bioluminescence imaging of xenograft models established with GSC267 cells treated with anti-CD47 and anti-IGFBP2 antibody on the indicated days after surgery. E In vivo tumor activities were assessed by bioluminescent in vivo imaging system on the indicated days after surgery. ( n = 5) F Kaplan-Meier survival curves for animals in different groups, n = 5 for each group. G A proposed model of hypoxia-exosomal IGFBP2-CD47 axis in the regulation of GBM immune evasion. Data are presented as the mean ± SD. Statistical significance was determined using one-way ANOVA and the log-rank test (* P < 0.05; ** P < 0.01; *** P < 0.001).

    Article Snippet: Treatments included tail vein injections of anti-CD47 reagent (BE0019, BioXcell), anti-IGFBP2 antibody (#AF674, R&D Systems), or isotype control antibody (#BP0089, BioXcell) three times a week after tumor implantation.

    Techniques: Flow Cytometry, Blocking Assay, Imaging, In Vivo, In Vivo Imaging